相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole
Nigel J. Bundred et al.
CANCER (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Survival in men with nonmetastatic prostate cancer treated with hormone therapy: A quantitative systematic review
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications
Tracey L. Krupski et al.
JOURNAL OF UROLOGY (2007)
Fracture risk in Danish men with prostate cancer: a nationwide register study
Bo Abrahamsen et al.
BJU INTERNATIONAL (2007)
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates
C. B. Confavreux et al.
BONE (2007)
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid
Christopher W. Ryan et al.
BJU INTERNATIONAL (2007)
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy
Christopher W. Ryan et al.
UROLOGY (2007)
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study
Manfred Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer - A randomized trial
Susan L. Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2007)
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer
Adam Brufsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer
Juan Morote et al.
UROLOGY (2007)
The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy
Ron S. Israeli et al.
CLINICAL GENITOURINARY CANCER (2007)
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
Michael F. X. Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study
Robert E. Coleman et al.
LANCET ONCOLOGY (2007)
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial
Susan L. Greenspan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane
S. Gonnelli et al.
BONE (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Androgen deprivation in veterans with prostate cancer: Implications for skeletal health
Andrew Wilcox et al.
ANNALS OF PHARMACOTHERAPY (2006)
Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study
J. Geisler et al.
EUROPEAN JOURNAL OF CANCER (2006)
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer
Christopher W. Ryan et al.
JOURNAL OF UROLOGY (2006)
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCICCTG MA.17
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors
Betty A. Mincey et al.
CLINICAL BREAST CANCER (2006)
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?
Sumapa Chaiamnuay et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2006)
Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression
J Morote et al.
JOURNAL OF UROLOGY (2006)
Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin
R Casey et al.
BONE (2006)
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2006)
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer
SL Greenspan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCICCTG MA.17
PE Goss et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer
LM Rodríguez-Rodríguez et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
R Jakesz et al.
LANCET (2005)
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial
F Boccardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A pilot study of bone density loss in menopausal women treated with chemotherapy for cancer
WR Robinson et al.
SUPPORTIVE CARE IN CANCER (2005)
Androgen deprivation therapy for prostate cancer
N Sharifi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Predictive value of BMD for hip and other fractures
O Johnell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Fracture risk in patients with prostate cancer on androgen deprivation therapy
AM López et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Assessment of fracture risk
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial
G El-Hajj Fuleihan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Aromatase inhibitors in the treatment of breast cancer
RW Brueggemeier et al.
ENDOCRINE REVIEWS (2005)
Preventing bone loss during androgen deprivation therapy for prostate cancer:: Early experience with neridronate
C Magno et al.
EUROPEAN UROLOGY (2005)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
A Howell et al.
LANCET (2005)
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats
PE Goss et al.
BONE (2004)
Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy
A Sverrisdóttir et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure
L Vehmanen et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats
PE Goss et al.
CLINICAL CANCER RESEARCH (2004)
Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy
TL Krupski et al.
CANCER (2004)
Osteoporosis and spinal fractures in men with prostate cancer: Risk factors and effects of androgen deprivation therapy
TH Diamond et al.
JOURNAL OF UROLOGY (2004)
Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition
MR Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effects of conadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer
Y Miyaji et al.
UROLOGY (2004)
Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression
C Higano et al.
UROLOGY (2004)
Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment
WP Olszynski et al.
CLINICAL THERAPEUTICS (2004)
Hip fractures in men with prostate cancer treated with orchiectomy
PW Dickman et al.
JOURNAL OF UROLOGY (2004)
Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors - A randomized, phase III, double-blind, placebo-controlled trial
LS Rosen et al.
CANCER (2004)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer
PR Sieber et al.
JOURNAL OF UROLOGY (2004)
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer
N Morabito et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue- and surgically castrated men with prostate cancer - A prospective, controlled, parallel-group study
I Bergstrom et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2004)
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
I Fogelman et al.
OSTEOPOROSIS INTERNATIONAL (2003)
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial
LS Rosen et al.
CANCER (2003)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2003)
The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer
NC Greep et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Fracture risk following bilateral orchiectomy
LJ Melton et al.
JOURNAL OF UROLOGY (2003)
Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment
J Morote et al.
EUROPEAN UROLOGY (2003)
Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation
SA Hussain et al.
BJU INTERNATIONAL (2003)
Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database
WF Anderson et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
Skeletal fractures negatively correlate with overall survival in men with prostate cancer.
MG Oefelein et al.
JOURNAL OF UROLOGY (2002)
Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy
A Berruti et al.
JOURNAL OF UROLOGY (2002)
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss
DM Preston et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2002)
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients.: The effect of adjuvant clodronate treatment
L Vehmanen et al.
EUROPEAN JOURNAL OF CANCER (2001)
Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer
MG Oefelein et al.
JOURNAL OF UROLOGY (2001)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
MR Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer
CL Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists
SA Stoch et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer
BJ Kiratli et al.
UROLOGY (2001)
Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer
T Hatano et al.
BJU INTERNATIONAL (2000)
Progressive osteoporosis during androgen deprivation therapy for prostate cancer
HW Daniell et al.
JOURNAL OF UROLOGY (2000)
分享论文
